# A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

> **NCT03157128** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 857 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Medullary Thyroid Cancer
- Colon Cancer
- Any Solid Tumor

## Interventions

- **DRUG:** LOXO-292

## Key facts

- **NCT ID:** NCT03157128
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-02
- **Primary completion:** 2025-02-14
- **Final completion:** 2027-02
- **Target enrollment:** 857 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03157128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03157128, "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03157128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*